138 results
Page 4 of 7
6-K
EX-99.1
58dqy8e
10 Aug 21
InflaRx Announces Positive Data from Second Interim Analysis
7:30am
6-K
EX-99.3
kyihc
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.2
omlfmf5
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.1
qdav 15rl
8 Jun 21
Current report (foreign)
7:30am
6-K
EX-99.1
lvr191147 6r5g1r0i
21 May 21
Tony Gibney Joins InflaRx Board of Directors
8:16am
6-K
EX-99.3
f5mvuqetga
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.2
jr1tn2
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.1
v3j4cz83ztllwr ja3
11 May 21
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study
4:30pm
6-K
EX-99.1
lrrxcmttwaxhwevf 1sd
15 Apr 21
InflaRx Completes Enrollment of Vilobelimab Phase IIa Study
7:30am
6-K
EX-99.1
hmtt 6x4u1
25 Mar 21
InflaRx Reports Full Year 2020 Financial & Operating Results
7:28am
424B5
8u6uxkdwkddvr dko
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
ji3diqjgrhgizhcbjdu
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
97o9id245qv02
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.1
f69w73
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am
6-K
EX-99.2
ge1i vvyft63akv8
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am
6-K
EX-99.1
fpxkl7qpic4hrjk060xi
5 Jan 21
InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
7:30am
6-K
EX-99.1
hnyit 9lawv06mpu20m2
29 Oct 20
Current report (foreign)
7:05am
6-K
EX-99.2
p5id4 jq72yjguc7t
29 Oct 20
Current report (foreign)
7:05am
6-K
EX-99.3
uzjuz w2s6j9
29 Oct 20
Current report (foreign)
7:05am